In January, Absci announced a strategic partnership and equity investment from Advanced Micro Devices, Inc. (AMD). The stock jumped over 40% on the news but gave back all of those gains within weeks.

Absci is preparing to send its first internally developed drug to clinical trials. The Vancouver-based biotechnology company released its annual financial results Tuesday, reporting earnings of $4 ...

Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci ...

In January 2025, entered into strategic collaboration with AMD to deploy AMD InstinctTM accelerators and ROCmTM software to power critical AI drug discovery workloads, including Absci's advanced ...

The company recently got a $20 million boost, an investment from chipmaker and Intel rival AMD. Absci went public in late July 2021 and its market cap rose to around $2.5 billion as shares nudged ...

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.

Absci (NASDAQ:ABSI) recently achieved a few milestones in healthcare AI as it received a $20 million investment from AMD to support Absci’s AI-driven drug discovery initiatives.

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.

On January 8, AMD entered a strategic collaboration with Absci Corporation, including a $20 million investment to support the company’s AI-driven drug discovery efforts.

Absci Corp. shares gained over 4% in the previous session, drawing the most retail interest among biotech stocks on Stocktwits after the company announced a strategic partnership with AMD, which ...

AMD’s Strategy: Aiming for Market Diversification AMD’s investment in Absci is part of a broader push to diversify its GPU offerings across various industries. The move follows a similar strategy ...